Synairgen’s inhaled COVID-19 treatment included in US trial
Trial is sponsored by the US National Institute of Allergy and Infectious Diseases (NIAID)
Read More
Tag: Synairgen
Synairgen begins large-scale trial of inhaled COVID-19 treatment
First patient in global trial dosed in the UK
Read More
Synairgen’s SNG001 shows strong promise in COVID-19 trial
The drug significantly cut the risk of developing severe disease and patients were twice as likely to recover versus placebo
Read More
AZ pulls plug on Phase II asthma trial
AstraZeneca has called time on a mid-stage trial assessing an experimental inhaled interferon beta licensed from Southampton, UK-based group Synairgen.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
